Behe vs. Mothra (no MRSA)

In a prior post DRG wonders how could Behe’s EoE inform the development of drugs that fight antibiotic resistant bacteria? Today’s WSJ, for example, describes the problem of MRSA and other superbugs that defy existing antibiotics. Given the expense of the pharmaceutical development process, an ID-oriented research program ought to reduce the cost of development by only focusing on drugs that would require resistant bacteria to evolve beyond the EoE (which Behe shows is not possible).  http://drugwonks.com/